We are live on ! Find out more
DARE icon

Dare Bioscience
DARE

30 hedge funds and large institutions have $6.1M invested in Dare Bioscience in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

11% more funds holding

Funds holding: 27 → 30 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.29% less ownership

Funds ownership: 1.01% → 0.72% (-0.29%)

9% less capital invested

Capital invested by funds: $6.67M → $6.1M (-$575K)

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

Holders
30
Holders Change
+3
Holders Change %
+11.11%
% of All Funds
0.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
6
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$335K
2
Squarepoint
Squarepoint
New York
+$289K
3
VF
Virtu Financial
New York
+$257K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$98K
5
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
+$50.8K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$3.21M
2
GCP
GSA Capital Partners
United Kingdom
-$193K
3
Goldman Sachs
Goldman Sachs
New York
-$186K
4
Citadel Advisors
Citadel Advisors
Florida
-$87K
5
Two Sigma Investments
Two Sigma Investments
New York
-$39K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.39M -$3.21M -131,494 -53%
Renaissance Technologies
2
Renaissance Technologies
New York
$1.47M +$335K +13,726 +23%
PVMCV
3
Polaris Venture Management Co V
Massachusetts
$551K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$438K +$98K +4,017 +23%
VF
5
Virtu Financial
New York
$253K +$257K +10,547 +550%
Squarepoint
6
Squarepoint
New York
$240K +$289K +11,844 New
Two Sigma Advisers
7
Two Sigma Advisers
New York
$211K +$18.3K +750 +8%
Northern Trust
8
Northern Trust
Illinois
$106K +$707 +29 +0.6%
IVM
9
InterWest Venture Management
California
$85K – – –
FFS
10
Founders Financial Securities
Maryland
$84K – – –
CIBC Private Wealth Group
11
CIBC Private Wealth Group
Georgia
$42K +$50.8K +2,083 New
Goldman Sachs
12
Goldman Sachs
New York
$41K -$186K -7,618 -79%
Charles Schwab
13
Charles Schwab
California
$35K +$40.9K +1,677 New
ECM
14
ExodusPoint Capital Management
New York
$32K +$38.2K +1,564 New
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
$28K +$33.8K +1,385 New
HighTower Advisors
16
HighTower Advisors
Illinois
$27K -$32.5K -1,334 -50%
UCFA
17
United Capital Financial Advisors
Texas
$21K -$2.02K -83 -8%
Citigroup
18
Citigroup
New York
$14K +$16.7K +683 New
FDCDDQ
19
Federation des caisses Desjardins du Quebec
Quebec, Canada
$8.45K -$3.05K -125 -23%
RFA
20
Reilly Financial Advisors
California
$4K -$8.39K -344 -63%
TRCT
21
Tower Research Capital (TRC)
New York
$4K -$4.83K -198 -50%
EWM
22
Edge Wealth Management
New York
$3K -$2.02K -83 -33%
AWA
23
Artemis Wealth Advisors
New York
$1.49K – – –
Osaic Holdings
24
Osaic Holdings
Arizona
$1K -$10.6K -436 -87%
BlackRock
25
BlackRock
New York
$1K – – –
1
2

DARE Hedge Fund Activity: Q1 2021 in Review

30 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q1 2021, worth a combined $6.1M — down 8.6% from $6.67M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new DARE positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 9 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $335K. The largest seller was Vanguard Group, cutting an estimated $3.21M.

  • 30 institutional investors held Dare Bioscience (DARE) as of Q1 2021, up from 27 in Q4 2020.
  • Funds reported $6.1M of Dare Bioscience stock for Q1 2021, down 8.6% quarter-over-quarter.
  • 9 funds opened new Dare Bioscience positions in Q1 2021 and 5 closed out, a net change of +4 holders.
  • The largest Dare Bioscience buyer in Q1 2021 was Renaissance Technologies, an estimated $335K added.
  • The largest Dare Bioscience seller in Q1 2021 was Vanguard Group, an estimated $3.21M sold.

Based on aggregated 13F filings for Q1 2021.